References

Center for Behavioral Health Statistics and Quality. Results from the 2015 National Survey on Drug Use and Health: Detailed Tables. Substance Abuse Center for Behavioral Health Statistics and Quality; Sep 2016.

Grotenhermen, F., Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet 2003, 42 (4), 327-60.

ElSohly, M. A.; Mehmedic, Z.; Foster, S.; Gon, C.; Chandra, S.; Church, J. C., Changes in Cannabis Potency Over the Last 2 Decades (1995-2014): Analysis of Current Data in the United States. Biol Psychiatry 2016, 79 (7), 613-9.

Barrus, D. G.; Capogrossi, K. L.; Cates, S. C.; Gourdet, C. K.; Peiper, N. C.; Novak, S. P.; Lefever, T. W.; Wiley, J. L., Tasty THC: Promises and Challenges of Cannabis Edibles. Methods Rep RTI Press 2016, 2016.

Garrett, E. R.; Hunt, C. A., Physiochemical properties, solubility, and protein binding of delta9-tetrahydrocannabinol. J Pharm Sci 1974, 63 (7), 1056-64.

Stout, S. M.; Cimino, N. M., Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review. Drug Metab Rev 2014, 46 (1), 86-95.

Geffrey, A. L.; Pollack, S. F.; Bruno, P. L.; Thiele, E. A., Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy. Epilepsia 2015, 56 (8), 1246-51.

Benowitz, N. L.; Nguyen, T. L.; Jones, R. T.; Herning, R. I.; Bachman, J., Metabolic and psychophysiologic studies of cannabidiol-hexobarbital interaction. Clin Pharmacol Ther 1980, 28 (1), 115-20.

arrow